<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2026.1749949</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A lytic bacteriophage vB_KpnP-6K2 inhibits ST11-KL64 <italic>Klebsiella pneumoniae</italic> induced cell death and inflammatory response</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Pan</surname><given-names>Zhaoyi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3273163/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Fan</surname><given-names>Jing</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Geng</surname><given-names>Xianbo</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Shujuan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Huijiao</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Shujun</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Ling</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3046094/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Xue</surname><given-names>Guangjian</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Rui</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Tianle</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Xiaofeng</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Yu</surname><given-names>Yating</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname><given-names>Na</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3241322/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jin</surname><given-names>Changzhong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wu</surname><given-names>Nanping</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Jinan Microecological Biomedicine Shandong Laboratory</institution>, <city>Jinan</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Shandong First Medical University and Shandong Academy of Medical Sciences</institution>, <city>Jinan</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine</institution>, <city>Hangzhou</city>,&#xa0;<country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Na Wang, <email xlink:href="mailto:wangna@jnl.ac.cn">wangna@jnl.ac.cn</email>; Changzhong Jin, <email xlink:href="mailto:jinchangzhong@jnl.ac.cn">jinchangzhong@jnl.ac.cn</email>; Nanping Wu, <email xlink:href="mailto:wunanping@jnl.ac.cn">wunanping@jnl.ac.cn</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-20">
<day>20</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>16</volume>
<elocation-id>1749949</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>28</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Pan, Fan, Geng, Zhang, Zhang, Liu, Zhang, Xue, Li, Li, Liu, Yu, Wang, Jin and Wu.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Pan, Fan, Geng, Zhang, Zhang, Liu, Zhang, Xue, Li, Li, Liu, Yu, Wang, Jin and Wu</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-20">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>The global dissemination of multidrug-resistant <italic>Klebsiella pneumoniae</italic> (<italic>Kpn</italic>) underscores the critical demand for alternative therapeutics such as bacteriophages. This study characterizes a novel bacteriophage, vB_KpnP-6K2 (6K2), isolated against a clinically relevant ST11-KL64 <italic>Kpn</italic> strain, and evaluates its potential for therapeutic application.</p>
</sec>
<sec>
<title>Methods</title>
<p>Phage 6K2 was morphologically examined by transmission electron microscopy and genomically analyzed via whole-genome sequencing. Its stability across pH and temperature ranges, adsorption kinetics, and burst size were determined <italic>in vitro</italic>. The inflammatory response to Kpn infection was assessed in HEK293T, A549, Hela, and THP-1 monocytic cells by measuring cytokine and chemokine expression, while cell death was evaluated in A549 lung epithelial cells. The therapeutic efficacy of 6K2 was tested in a lethal murine systemic infection model, where a single intraperitoneal dose was administered one-hour post-bacterial challenge. Survival, bacterial clearance, and phage kinetics in blood were monitored.</p>
</sec>
<sec>
<title>Results</title>
<p>Phage 6K2 exhibits a polyhedral head and short tail, classifying it within the Podoviridae family (Autographiviridae family, <italic>Przondovirus</italic> genus). Its double-stranded DNA genome comprises 40,147 bp. The phage demonstrated stability across a broad pH (4-12) and temperature (4-50&#xb0;C) range, rapid adsorption, and a burst size of 13.6 PFU/cell. <italic>In vitro</italic>, <italic>Kpn</italic> infection significantly upregulated inflammatory mediators in THP-1 cells and induced death in A549 cells; both responses were potently inhibited by 6K2 treatment. In the murine infection model, a single dose of 6K2 achieved 100% survival, accompanied by rapid clearance of bacteremia and high initial phage titers in the blood.</p>
</sec>
<sec>
<title>Discussion</title>
<p>These findings highlight the promising potential of bacteriophage 6K2 as an effective therapeutic agent against multidrug-resistant <italic>Kpn</italic> infections. The phage not only suppresses bacterial load but also mitigates infection-associated inflammatory responses and cellular damage. The complete rescue in a lethal systemic infection model underscores it&#x2019;s <italic>in vivo</italic> efficacy and supports further development of phage-based strategies for combating resistant bacterial infections.</p>
</sec>
</abstract>
<kwd-group>
<kwd>bacteriophage</kwd>
<kwd>bloodstream infections</kwd>
<kwd>cell death</kwd>
<kwd>inflammatory response</kwd>
<kwd><italic>Klebsiella pneumoniae</italic></kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>Natural Science Foundation of Shandong Province</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100007129</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="sp1">ZR2023QH546</award-id>
</award-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was supported by Shandong Provincial Natural Science Foundation (grant number ZR2023QH546); and the Research Project of Jinan Microecological Biomedicine Shandong Laboratory (grant numbers JNL-2022004Q, JNL-2023014D, JNL-2025005B); and the project supported by the National Key R&amp;D Program of China (2023YFC2506004); and the Shandong Provincial Laboratory Project (grant number SYS202202).</funding-statement>
</funding-group>
<counts>
<fig-count count="8"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="54"/>
<page-count count="12"/>
<word-count count="5276"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Antibiotic Resistance and New Antimicrobial drugs</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p><italic>Klebsiella pneumoniae</italic> (<italic>Kpn</italic>) represents a predominant cause of antimicrobial-resistant opportunistic infections among hospitalized patients, owing to its remarkable capacity to acquire exogenous genetic elements encoding both resistance and hypervirulence (<xref ref-type="bibr" rid="B43">Wyres et&#xa0;al., 2020</xref>; <xref ref-type="bibr" rid="B45">Yang X. et&#xa0;al., 2021</xref>). As a key contributor to&#xa0;the global antibiotic resistance crisis, <italic>Kpn</italic> is implicated in more than 100,000 deaths annually worldwide. Strains resistant to carbapenems and third-generation cephalosporins represent particularly urgent threats to public health (<xref ref-type="bibr" rid="B2">Antimicrobial Resistance, 2022</xref>). The majority of <italic>Kpn</italic> strains are encapsulated by polysaccharide capsular material (CPS), a critical virulence&#xa0;determinant. Based on CPS variation, <italic>Kpn</italic> can be classified into at least 78 distinct serotypes (<xref ref-type="bibr" rid="B51">Zhao R. et&#xa0;al., 2024</xref>). Genomic and epidemiological analyses of 1,649 <italic>Kpn</italic> isolates from 244 hospitals across 32 European countries revealed that carbapenemase production represents the primary mechanism driving carbapenem resistance across diverse phylogenetic lineages (<xref ref-type="bibr" rid="B12">David et&#xa0;al., 2019</xref>). Nonetheless, the vast majority of carbapenemase-producing isolates belong to only four major clonal lineages-sequence types (STs) 11, 15, 101, and 258/512-and their derivatives (<xref ref-type="bibr" rid="B12">David et&#xa0;al., 2019</xref>).</p>
<p>Bacteriophages (phages), naturally occurring viruses that specifically infect bacterial hosts, are categorized into lysogenic and lytic types based on their mechanisms of infection. Phage therapy provides a promising complement to antibiotics against multidrug-resistant (MDR) bacterial infections (<xref ref-type="bibr" rid="B34">Torres-Barcelo and Hochberg, 2016</xref>; <xref ref-type="bibr" rid="B7">Chegini et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B14">Fang et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B52">Zhao M. et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B22">Huang et&#xa0;al., 2025</xref>). In recent years, significant progress has been made in phage therapy for treating and preventing pathogenic bacterial infections, attracting increasingly widespread attention (<xref ref-type="bibr" rid="B13">Duan et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B21">Hatfull et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B35">Uyttebroek et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B32">Strathdee et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B15">Fang et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B3">Berryhill et&#xa0;al., 2025</xref>). Compared with antibiotic treatments, phage therapy remains efficacy against drug-resistant pathogens. Moreover, phage therapy can specifically target pathogenic bacteria while sparing the resident microbiota, thereby preserving the integrity of the host&#x2019;s microbial community.</p>
<p><italic>Kpn</italic> is a gram-negative pathogen that contain lipopolysaccharides (LPS), peptidoglycans, periplasmic, cytoplasmic proteins, capsular polysaccharide, and nucleic acids (<xref ref-type="bibr" rid="B44">Xu et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B25">Li et&#xa0;al., 2025</xref>). LPS was regarded as an important factor that induces inflammation among Gram-negative bacteria by promoting Toll like receptor 4 (TLR4) signaling pathway activation (<xref ref-type="bibr" rid="B30">Ryu et&#xa0;al., 2017</xref>). Attenuating TLR4 induced inflammation could alleviate <italic>Kpn</italic>-induced pneumonia (<xref ref-type="bibr" rid="B40">Wei et&#xa0;al., 2025</xref>). As a new approach to combat <italic>Kpn</italic>, phage therapy has exhibited positive clinical effects in some animal experiments and small-scale clinical studies (<xref ref-type="bibr" rid="B17">Federici et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B24">Li et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B9">Chen et&#xa0;al., 2024</xref>). However, the interactions among phage, <italic>Kpn</italic>, and <italic>Kpn</italic>&#x2212;infected host cells warrant further investigation. In this study, we isolated a <italic>Kpn</italic>&#x2212;specific bacteriophage and examined its capacity to mitigate <italic>Kpn</italic>&#x2212;induced inflammation and cell death. We also assessed the phage&#x2019;s therapeutic performance in a mouse model of <italic>Kpn</italic> infection.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s2_1">
<title>Cells</title>
<p>HEK293T, A549, THP-1 and Hela cells were obtained from the American Type Culture Collection. HEK293T, A549 cells and Hela cells were grown in Dulbecco&#x2019;s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics (penicillin and streptomycin) at 37 &#xb0;C in 5% CO2. THP-1 cells were grown in RPMI-1640 supplemented with 10% FBS and 1% antibiotics (penicillin and streptomycin) at 37 &#xb0;C in 5% CO2.</p>
</sec>
<sec id="s2_2">
<title>Phage isolation and purification</title>
<p>A novel lytic phage, named vB_KpnP-6K2 (6K2), was screened from hospital sewage samples using a ST11-KL64 type <italic>Kpn</italic> as the host bacterium. In brief, sewage samples were centrifuged at 4,000 &#xd7; g for 10 min. The resulting supernatant was filtered through a 0.22 &#xb5;m membrane (Millex-GP Filter Unit, Millipore, USA). Subsequently, 5 mL of the filtrate was combined with 5 mL of double-strength LB broth supplemented with host bacteria and incubated overnight at 37 &#xb0;C. After incubation, the mixture was centrifuged at 4,000 &#xd7; g for 10 min, and the supernatant was again filtered through a 0.22 &#xb5;m filter. The filtrate was serially diluted in LB medium, and plaques were observed using the double-layer agar method. The purification procedure was repeated at least three times until homogeneous phage plaques were observed. Finally, SM buffer containing purified phage was centrifuged for 10 min at 4,000&#xd7; g and filtered through a 0.22 &#xb5;m syringe-driven filter. The supernatant was added with 10% glycerol and stored at -80 &#xb0;C (<xref ref-type="bibr" rid="B19">Garcia-Cruz et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B1">Abdel-Razek et&#xa0;al., 2025</xref>; <xref ref-type="bibr" rid="B26">Mirza et&#xa0;al., 2025</xref>).</p>
</sec>
<sec id="s2_3">
<title>Multiplicity of infection assay</title>
<p>To determine the optimal multiplicity of infection (MOI) for maximizing phage progeny yield, the host strain <italic>Kpn</italic> was grown to logarithmic phase and adjusted to a turbidity equivalent to 0.5 McFarland standard (approximately 10<sup>8</sup> CFU/mL). A volume of 10 mL of the host bacterial suspension at 10<sup>7</sup> CFU/mL was mixed with 10 &#x3bc;L of serially diluted phage suspensions (approximately 10<sup>7</sup>, 10<sup>6</sup>, 10<sup>5</sup>, 10<sup>4</sup>, 10<sup>3</sup>, 10<sup>2</sup>, 10<sup>1</sup>, and 10<sup>0</sup> PFU/mL), as previously described (<xref ref-type="bibr" rid="B54">Zhou et&#xa0;al., 2018</xref>). After 6 hours of incubation, the number of progeny phages was quantified using the double-layer agar method.</p>
</sec>
<sec id="s2_4">
<title>pH and thermal stability</title>
<p>We evaluated the stability of phage under varying pH conditions and temperatures as previously described (<xref ref-type="bibr" rid="B16">Fang and Zong, 2022</xref>). Phage suspensions (100 &#x3bc;L) at a concentration of 10<sup>9</sup> PFU/mL were mixed with 900 &#x3bc;L of SM buffer adjusted to different pH values ranging from 2 to 13. After incubation at 37 &#xb0;C for 1 hour, the phage titer was quantified using the double-layer agar method. Thermal stability was assessed by incubating phage suspensions at -20, 4, 37, 50, 60, and 70 &#xb0;C for 1 hour in a water bath, followed by titer determination as described above. All experiments were conducted in triplicate.</p>
</sec>
<sec id="s2_5">
<title>Transmission electron microscopy</title>
<p>We observed the morphology and the size of phage 6K2 using transmission electron microscopy (TEM) imaging. Lysates of phage 6K2 were centrifuged at 16,000&#xd7; g for 10 min and supernatants were filtered through 0.22 &#xb5;m to remove bacteria and cell debris. This procedure yielded a final phage titer of 1 &#xd7; 10<sup>9</sup> PFU/mL. We dropped the phage suspension to copper grids for 10 min and then added a drop of phosphotungstic acid (Solarbio, Cat: G1872) for negative staining. We used a Hitachi Transmission Electron Microscope (Hitachi High-Tech; Tokyo, Japan) at an accelerating voltage of 80 kV for TEM.</p>
</sec>
<sec id="s2_6">
<title>Phage adsorption and one-step growth</title>
<p>We assessed the phage adsorption capability by combining 10 mL of the <italic>Kpn</italic> (10<sup>8</sup> CFU/mL) with 100 &#x3bc;L of phage suspension (10<sup>8</sup> PFU/mL) at a MOI of 0.01. Samples were collected at 0-, 3-, 6-, 9-, 12-, and 15-min post-infection and immediately filtered through 0.22 &#xb5;m membranes to determine the titers of unabsorbed phages. Host bacteria at the mid-log phase were infected with phages at an MOI of 0.01 and adsorbed for 10 min at 37 &#xb0;C. After removing unabsorbed phages by centrifugation, the infected cells were resuspended in fresh medium to a 10-fold dilution. The diluted culture was incubated at 37 &#xb0;C with shaking, and samples were collected at indicated time points. Each sample was immediately serially diluted and assayed for PFU using the double-agar overlay method.</p>
</sec>
<sec id="s2_7">
<title>Phage genome sequencing, assembly, and annotation</title>
<p>The DNA of phage 6K2 was extracted using a Viral Genome Extraction Kit (Tiangen, China) and sent to Chengdu Phagetimes Biotech Co., Ltd., and the genome was sequenced using an Illumina Novaseq 6000. Raw sequencing reads were processed for quality control and adapter trimming using fastp (<xref ref-type="bibr" rid="B8">Chen et&#xa0;al., 2018</xref>). This step removed low-quality reads and reads with a high proportion of ambiguous bases (N), yielding high-quality clean reads. <italic>De novo</italic> assembly of the clean reads was performed with metaSPAdes (<xref ref-type="bibr" rid="B28">Nurk et&#xa0;al., 2017</xref>). Based on the assembled contig sequence, specific primers spanning the terminal region were designed to verify the genome is circular or not (<xref ref-type="bibr" rid="B4">Boeckman et&#xa0;al., 2024</xref>). The primer sequences used were 6K2-end-F: 5&#x2019;-CGTATGTCCGGTTGATGACTAC-3&#x2019; and 6K2-end-R: 5&#x2019;- CTATGCACTGACCTGAGGATTAC-3&#x2019;. Following PCR amplification, the product was purified and its sequence was determined by Sanger sequencing.</p>
<p>The assembled genome was annotated for protein-coding genes and tRNAs using the RAST server (<ext-link ext-link-type="uri" xlink:href="https://rast.nmpdr.org/">https://rast.nmpdr.org/</ext-link>), and the annotation was further verified by Blastp. Potential virulence factors and antimicrobial resistance genes were identified by screening the genome sequences against the Virulence Factor Database (VFDB) and the ResFinder database, respectively. Finally, the phage genome was visualized using an online Circos tool (<ext-link ext-link-type="uri" xlink:href="https://www.chiplot.online/circos.html">https://www.chiplot.online/circos.html</ext-link>).</p>
</sec>
<sec id="s2_8">
<title>Assessment of apoptosis by flow cytometry</title>
<p>A549 cells were seeded in 12-well plates at a density of approximately 1&#xd7;10<sup>5</sup> cells per well. After 12 hours, the culture medium was replaced with DMEM supplemented with 10% FBS&#xa0;and without antibiotics. The cells were then infected with 5 &#x3bc;L of <italic>Kpn</italic> containing approximately 1&#xd7;10<sup>6</sup> CFU, while the control group received an equivalent volume of sterile LB medium. Following co-culture for 12 and 24 hours, cells were harvested and stained by Cell Cycle and Apoptosis Analysis Kit (Yeasen, 40301ES50) to analyze the apoptosis by flow cytometry (<xref ref-type="bibr" rid="B11">Crowley&#xa0;et&#xa0;al., 2016</xref>).</p>
</sec>
<sec id="s2_9">
<title>Detection of inflammatory cytokine and chemokine expression by qPCR</title>
<p>Total RNA was extracted using TRIzol reagent (<xref ref-type="bibr" rid="B29">Rio et&#xa0;al., 2010</xref>) and reverse-transcribed to cDNA for qPCR analysis to measure mRNA levels of the indicated genes. The mRNA levels of the tested genes were normalized to 18S rRNA levels. Gene-specific primer sequences were as follows:</p>
<list list-type="simple">
<list-item>
<p><italic>18S</italic>: CCGGTACAGTGAAACTGCGAATG (forward) and</p></list-item>
<list-item>
<p>GTTATCCAAGTAGGAGAGGAGCGAG (reverse),</p></list-item>
<list-item>
<p><italic>IL1B</italic>: CCACAGACCTTCCAGGAGAATG (forward) and</p></list-item>
<list-item>
<p>GTGCAGTTCAGTGATCGTACAGG (reverse),</p></list-item>
<list-item>
<p><italic>IL6</italic>: AGACAGCCACTCACCTCTTCAG (forward) and</p></list-item>
<list-item>
<p>TTCTGCCAGTGCCTCTTTGCTG (reverse),</p></list-item>
<list-item>
<p><italic>TNFA</italic>: CTCTTCTGCCTGCTGCACTTTG (forward) and</p></list-item>
<list-item>
<p>ATGGGCTACAGGCTTGTCACTC (reverse),</p></list-item>
<list-item>
<p><italic>CXCL1</italic>: AGCTTGCCTCAATCCTGCATCC (forward) and</p></list-item>
<list-item>
<p>TCCTTCAGGAACAGCCACCAGT (reverse),</p></list-item>
<list-item>
<p><italic>CXCL2</italic>: GGCAGAAAGCTTGTCTCAACCC (forward) and</p></list-item>
<list-item>
<p>CTCCTTCAGGAACAGCCACCAA (reverse),</p></list-item>
<list-item>
<p><italic>CXCL3</italic>: TTCACCTCAAGAACATCCAAAGTG (forward) and</p></list-item>
<list-item>
<p>TTCTTCCCATTCTTGAGTGTGGC (reverse),</p></list-item>
<list-item>
<p><italic>CXCL5</italic>: CAGACCACGCAAGGAGTTCATC (forward) and</p></list-item>
<list-item>
<p>TTCCTTCCCGTTCTTCAGGGAG (reverse),</p></list-item>
<list-item>
<p><italic>CXCL8</italic>: GAGAGTGATTGAGAGTGGACCAC (forward) and</p></list-item>
<list-item>
<p>CACAACCCTCTGCACCCAGTTT (reverse),</p></list-item>
<list-item>
<p><italic>CXCL10</italic>: GGTGAGAAGAGATGTCTGAATCC (forward) and</p></list-item>
<list-item>
<p>GTCCATCCTTGGAAGCACTGCA (reverse),</p></list-item>
<list-item>
<p><italic>CXCL12</italic>: CTCAACACTCCAAACTGTGCCC (forward) and</p></list-item>
<list-item>
<p>CTCCAGGTACTCCTGAATCCAC (reverse),</p></list-item>
<list-item>
<p><italic>IFNB</italic>: GACAGGATGAACTTTGACATCCC (forward) and</p></list-item>
<list-item>
<p>CTCAACAATAGTCTCATTCCAGCC (reverse),</p></list-item>
<list-item>
<p><italic>ISG54</italic>: GGAGCAGATTCTGAGGCTTTGC (forward) and</p></list-item>
<list-item>
<p>GGATGAGGCTTCCAGACTCCAA (reverse).</p></list-item>
</list>
</sec>
<sec id="s2_10">
<title>Mice experiments</title>
<p>Six-week-old male C57BL/6J mice were divided into seven groups (n = 10 per group) and intraperitoneally (IP) injected with 200 &#x3bc;L of <italic>Kpn</italic> at doses of 5 &#xd7; 10<sup>5</sup>, 1 &#xd7; 10<sup>6</sup>, 5 &#xd7; 10<sup>6</sup>, 1 &#xd7; 10<sup>7</sup>, 1 &#xd7; 10<sup>7</sup>, 5 &#xd7; 10<sup>7</sup>, or 1 &#xd7; 10<sup>8</sup> CFU. Control mice received an equal volume of PBS. Survival and body weight changes were monitored over time.</p>
<p>In an independent experiment, six-week-old male C57BL/6J mice were allocated into six groups and intraperitoneally challenged with 200 &#x3bc;L of <italic>Kpn</italic> at 1 &#xd7; 10<sup>8</sup> CFU (n &#x2265; 5 per group) or with PBS (n =3 per group). 1h later, 6K2 was administered at MOI of 0, 1 and 10. Mice in the MOI = 0 group received an equivalent volume of PBS as control. Survival was recorded every 3 h for all mice. In the <italic>Kpn</italic>&#x2212;infected group, blood samples were collected at 1, 6, and 24h post phage administration to quantify bacterial load (CFU/mL) by plate counting and phage titers (PFU/mL) using the double-layer agar method. For mice not infected with <italic>Kpn</italic>, blood samples were collected solely for monitoring phage titer changes by the double&#x2212;layer agar assay. All animal experiments were carried out in Jinan Microecological Biomedicine Shandong Laboratory (Jinan, China) according to procedures approved by the institutional ethics committee (Animal testing approval number:2026001).</p>
</sec>
<sec id="s2_11">
<title>Statistical analysis</title>
<p>Statistical significance was calculated using an unpaired Student&#x2019;s t test (two-tailed). Results are shown as arithmetic means &#xb1; SD of at least 3 or more independent measurements. GraphPad Prism 9 was used for statistical analysis.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Morphology of phage 6K2</title>
<p>The bacteriophage 6K2 was isolated from hospital sewage using a ST11-KL64 type <italic>Kpn</italic> as the host bacterium. Purified phage 6K2 formed clear plaques (the diameter about 4 mm) with translucent halos (the diameter about 3 mm) on double-layer agar plates (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1A</bold></xref>). Transmission electron microscopy (TEM) revealed that bacteriophage 6K2 had a polyhedral symmetric head (the head diameter was approximately 60 nm) and a short non-contractile tail (the tail length was 15 nm and the width was 15 nm), which is a typical morphology of the family <italic>Podoviridae</italic> (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1B</bold></xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Morphology of phage 6K2. <bold>(A)</bold> Plaques formed by phage 6K2 on <italic>Kpn</italic> host using the double agar overlay method. <bold>(B)</bold> Transmission electron microscopy (TEM) image of phage 6K2. The head diameter was approximately 60 nm, with a tail measuring 15 nm in length and 15 nm in width. Scale bar: 100 nm. <bold>(C)</bold> Genomic maps of phage 6K2. Genome was annotated using the RAST server. ORF positions are represented by colored bars on concentric rings, with the specific ring (inner or outer) indicating the direction of transcription. Functional categories are distinguished by color, as detailed in the legend. The circular genome map was generated using an online Circos tool (<ext-link ext-link-type="uri" xlink:href="https://www.chiplot.online/circos.html">https://www.chiplot.online/circos.html</ext-link>).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1749949-g001.tif">
<alt-text content-type="machine-generated">Panel A shows a petri dish with bacterial growth and multiple clear plaques, alongside a ruler for scale. Panel B presents a grayscale transmission electron microscopy image of a spherical bacteriophage with a visible tail structure. Panel C is a genome map of bacteriophage 6K2, displaying GC skew, GC content, and functional annotations, with a legend classifying coding sequences by color into categories such as regulation, replication, lysis, infection, immune, packaging, assembly, and other.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_2">
<title>Genome features and annotation</title>
<p><italic>De novo</italic> assembly of the 6K2 genome produced a single contig of 40,328 bp, which featured terminal repeats of 181 bp at both ends. To determine whether this structure represented a linear genome with redundant termini or a circular conformation, we performed PCR with primers spanning the repeat junction. Sanger sequencing of the amplicon confirmed a circular genome structure. The complete, circularized double-stranded DNA genome comprises 40,147 bp with a GC content of 53.05% (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1C</bold></xref>; see Additional file 1 for sequence verification details). Phage 6K2 has 48 predicted open reading frames (ORFs), with 32 ORFs (68.1%) annotated with predicted functions (Additional file 2). The annotated genes of 6K2 were categorized into different functional groups, including phage infection, DNA replication and regulation, phage capsid assembly, DNA packaging and host lysis (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1C</bold></xref>). In addition, no homologs of known virulence factors or antibiotic resistance genes were identified in the 6K2 genome, suggesting its potential suitability for clinical applications.</p>
<p>The phylogenetic relatedness of 6K2 with similar phages was determined based on genome-wide sequence similarities calculated by tBLASTx with the use ViPTree (<ext-link ext-link-type="uri" xlink:href="https://www.genome.jp/viptree/">https://www.genome.jp/viptree/</ext-link>). 6K2 was clustered with <italic>Klebsiella</italic> phage vB <italic>Kpn</italic>16-P1, vB <italic>Kpn</italic>16-P3, vB Kp IME531 and Kp 11 (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>). Based on these results and&#xa0;the viral classification provided by the International Committee on Taxonomy of Viruses (ICTV), it was concluded that 6K2 belongs&#xa0;to the family of <italic>Autographiviridae</italic>, within the genus of <italic>Przondovirus</italic>.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Phylogenetic tree of 6K2 and relative bacteriophages based on the complete genome sequences. The tree was constructed using the ViPTree. The red star indicates the phage 6K2.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1749949-g002.tif">
<alt-text content-type="machine-generated">Circular phylogenetic tree diagram showing relationships among Klebsiella phages. The inner ring uses colors to represent virus families, while the outer ring identifies host groups, with green for Pseudomonadota. A red arrow points to phage 6K2 H0.328 n1. A legend in the top left defines ring color codings.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_3">
<title>Characterization of phage 6K2</title>
<p>To determine the efficiency of phage 6K2 in killing the <italic>Kpn</italic>, we examined its inhibitory effects at varying doses. Complete inhibition of <italic>Kpn</italic> by 6K2 was observed at MOIs ranging from 0.001 to 10 (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3A</bold></xref>). During the first 2 hours post-infection, the group of 6K2 (MOI&#x2265;0.1) effectively suppressed <italic>Kpn</italic> growth. After this initial period, however, bacterial loads in groups with an MOI &lt;0.1 also became suppressed, resulting in no significant difference compared to the higher MOI groups. The results of pH and thermal stability showed that 6K2 has a wide pH tolerance, which is ranging from 4 to 12 (no significant differences among the four groups tested at pH 6, pH 7, pH 8, and pH 10) (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3B</bold></xref>). Although with minimal loss in titer, 6K2 remained active between 4 &#xb0;C and 50 &#xb0;C. However, the phage titer of 6K2 decreased by 5 log and 7 log after incubation of 1 hour at 60 &#xb0;C and 70 &#xb0;C, respectively (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3C</bold></xref>). No viable phage particles were detected following treatment at 80 &#xb0;C (data not show). This suggests that phage 6K2 is less tolerant to the temperatures above 60 &#xb0;C. The one-step growth curve analysis demonstrated the latent period of 6K2 lasted for about 40 min and followed by a burst period lasted for about 80 min (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3D</bold></xref>). And the burst size was calculated as 13.6 PFU per host cell. The optimal multiplicity of infection (MOI) was 0.01 of 6K2 vs <italic>Kpn</italic> (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3E</bold></xref>). Phage adsorption measurements showed that about 80% phages absorbed to host cells at 3 min and almost all phages absorbed to host cells after 6 min (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3F</bold></xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Characterization of phage 6K2. <bold>(A)</bold> The bacteriolytic activity of 6K2 <italic>in vitro</italic>. <bold>(B)</bold> pH stability detection of 6K2. <bold>(C)</bold> Temperature stability of 6K2. <bold>(D)</bold> One-step growth curve of 6K2. <bold>(E)</bold> The optimal multiplicity of infection. <bold>(F)</bold> Absorption rate of 6K2.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1749949-g003.tif">
<alt-text content-type="machine-generated">Six-panel scientific figure showing: A, a line graph of bacterial growth over time under different multiplicities of infection (MOIs); B, a bar graph of phage stability at various pH values; C, a bar graph of phage stability at different temperatures; D, a line graph of phage titer over time; E, a bar graph of phage titer across a range of MOIs; F, a line graph of percentage of free phage decreasing over time.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_4">
<title>Monocyte is responsible for the inflammation after <italic>Kpn</italic> infection</title>
<p>Infections caused by <italic>Kpn</italic> encompass a broad spectrum of clinical manifestations, including renal impairment in kidney transplant recipients, pulmonary infections leading to pneumonia, bloodstream and intra-abdominal infections resulting in sepsis (<xref ref-type="bibr" rid="B46">Yang Y. et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B49">Zhang et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B53">Zheng et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B33">Tang et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B47">Yang YY. et&#xa0;al., 2024</xref>). Therefore, we assessed the ability of <italic>Kpn</italic> and its culture supernatant to induce inflammatory responses in various cell types. Our results demonstrated that <italic>Kpn</italic> and its culture supernatant treatment only promote <italic>IL1B</italic>, <italic>TNFA</italic> and <italic>IL6</italic> expression in THP-1 (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4A</bold></xref>). During the initial phase of an infection, resident cells release chemokines that recruit diverse immune cells to the site of infection, where they exert their effector functions (<xref ref-type="bibr" rid="B5">Borish and Steinke, 2003</xref>; <xref ref-type="bibr" rid="B36">van der Vorst et&#xa0;al., 2015</xref>). Furthermore, we also assessed the chemokines expression induced by <italic>Kpn</italic> and its culture supernatant. Treatment with <italic>Kpn</italic> or its supernatant upregulates chemokine expression in THP-1 and A549 cells, but not in HEK293T or HeLa cells (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4B-E</bold></xref>). Notably, <italic>CXCL5</italic> and <italic>CXCL10</italic> induction was absent in THP-1 cells (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4C</bold></xref>), while <italic>CXCL2</italic> and <italic>CXCL12</italic> were not induced in A549 cells (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4D</bold></xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Inflammatory responses in various cell types induced by <italic>Kpn</italic>. <bold>(A)</bold> HEK293T, A549, Hela, THP-1 cells were treated with <italic>Kpn</italic> and its culture supernatant for 12h. the cells were collected for qPCR assay to detect the <italic>IL1B</italic>, <italic>TNFA</italic>, and <italic>IL6</italic> expression. <bold>(B&#x2013;E)</bold> HEK293T, A549, Hela, THP-1 cells were treated with <italic>Kpn</italic> and its culture supernatant for 12h. the cells were collected for qPCR assay to detect the <italic>CXCL1, CXCL2, CXCL3, CXCL5, CXCL8, CXCL10</italic>, and <italic>CXCL12</italic> expression. mock: cells were treated with an equal volume of LB medium.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1749949-g004.tif">
<alt-text content-type="machine-generated">Composite bar graph figure displaying relative mRNA fold changes for inflammatory genes (IL1B, TNFA, IL6) and CXCL genes across 293T, A549, Hela, and THP-1 cell lines after mock, Kpn-S, or Kpn treatment. Y-axes show relative mRNA fold levels and data points are color-coded: mock (red), Kpn-S (green), Kpn (blue). Prominent induction, especially by Kpn, is observed for THP-1 cells in most markers, notably CXCL8 and CXCL10. Error bars and individual data points are included for all groups.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_5">
<title>6K2 reduces cytokines and chemokine expression during <italic>Kpn</italic> infection</title>
<p>After 6 hours incubation of <italic>Kpn</italic> and THP-1 at 37 &#xb0;C, cell culture medium (RPMI 1640 cell culture medium with 10% FBS) exhibited acidification. Treatment with 6K2 significantly alleviated the medium acidification induced by <italic>Kpn</italic> infection (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5A</bold></xref>). Acidification of the cell culture medium serves as an indicator of <italic>Kpn</italic> proliferation. In order to determine 6K2 on the inflammation and chemokine expression induced by <italic>Kpn</italic> infection. qPCR assay was performed, our results demonstrated that 6K2 markedly suppressed the <italic>IL1B</italic> and <italic>TNFA</italic> expression significantly but not <italic>IL6</italic> (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5B</bold></xref>). Moreover, 6K2 suppressed the expression of chemokines (<italic>CXCL1</italic>, <italic>CXCL2</italic>, and <italic>CXCL3</italic>) following <italic>Kpn</italic> infection (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5C</bold></xref>). In contrast, our data demonstrate that 6K2 potentiated the upregulation of <italic>CXCL10</italic> in response to <italic>Kpn</italic> infection (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5D</bold></xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>6K2 Reduces cytokines and chemokine expression during <italic>Kpn</italic> infection. <bold>(A)</bold><italic>Kpn</italic> and THP-1 cells were co-cultured in RPMI 1640 supplemented with 10% FBS at 37 &#xb0;C for 6 h, and the culture supernatant was subsequently imaged. <bold>(B&#x2013;D)</bold><italic>Kpn</italic> and THP-1 cells were co-cultured under the same conditions in the presence or absence of 6K2 for 12 h, after which cells were harvested for qPCR to analysis the cytokines <bold>(B)</bold> and chemokine <bold>(C, D)</bold> expression. mock: cells were treated with an equal volume of LB medium and SM buffer.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1749949-g005.tif">
<alt-text content-type="machine-generated">Panel A displays a photograph of a nine-well plate showing three treatment conditions: mock, control (Ctrl), and 6K2. Panels B, C, and D present bar graphs with individual data points displaying relative mRNA fold changes for IL1B, TNFA, IL6, CXCL1, CXCL2, CXCL3, and CXCL10 in THP1 cells under the same three conditions. Control groups exhibit high gene expression for most analytes, with 6K2 generally showing reduced responses except for CXCL10, which is elevated versus control.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_6">
<title>6K2 promotes antiviral innate immunity and inflammatory response activation</title>
<p>To further investigate whether 6K2 inhibits inflammation by clearing Klebsiella pneumoniae infection or exerts direct anti-inflammatory effects, we treated THP-1 cells with heat-killed <italic>Kpn</italic> to induce inflammation. We found that 6K2 did not suppress the expression of inflammatory cytokines and chemokines induced by heat-killed <italic>Kpn</italic>. Moreover, 6K2 itself could also induce the&#xa0;expression of inflammatory cytokines and chemokines (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6A, B</bold></xref>). To determine whether phage 6K2 acts as a viral agent that triggers interferon-mediated antiviral immune responses, we performed qPCR analysis and observed that 6K2 induced the&#xa0;expression of <italic>IFNB</italic> and interferon-stimulated gene <italic>ISG54</italic> (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6C</bold></xref>).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>6K2 promotes antiviral innate immunity and inflammatory response activation. <bold>(A-C)</bold> THP-1 cells were treated with heat-killed <italic>Kpn</italic> and bacteriophage 6K2, while control groups received equivalent volumes of LB medium and PBS, respectively. After 12 hours, cells were harvested, and the expression of inflammatory cytokines (<italic>IL1B, TNFA</italic>) <bold>(A)</bold>, chemokines (<italic>CXCL3, CXCL8</italic>) <bold>(B)</bold>, and interferon pathway antiviral genes (<italic>IFNB, ISG54</italic>) <bold>(C)</bold> was analyzed by qPCR.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1749949-g006.tif">
<alt-text content-type="machine-generated">Six grouped bar graphs illustrate relative mRNA fold changes for IL1B, TNFA, CXCL3, CXCL8, IFNB, and ISG54 in THP1 cells, comparing four experimental conditions involving 6K2 and Kpn. Distinct color bars represent each condition, with highest expression observed when both factors are present.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_7">
<title>6K2 inhibits cell death induced by <italic>Kpn</italic> infection</title>
<p>Previous studies have demonstrated that <italic>Kpn</italic> infection could induce cell death by promoting apoptosis, pyroptosis, and autophagy (<xref ref-type="bibr" rid="B37">Wang et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B23">Jiang et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B38">Wang et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B39">Wei et&#xa0;al., 2023</xref>). Therefore, we further investigated the impact of <italic>Kpn</italic> infection on cell death. Initially, co-culture of <italic>Kpn</italic> with A549 cells was found to promote acidification of the culture medium, while 6K2 inhibited this <italic>Kpn</italic>-induced acidification (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7A</bold></xref>). Further examination of the <italic>Kpn</italic> in the co-culture system revealed that 6K2 significantly reduced <italic>Kpn</italic> proliferation (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7B</bold></xref>). Microscopic observation of A549 cell morphology showed that <italic>Kpn</italic> induced cell rounding, fragmentation, and death, whereas 6K2 markedly alleviated these morphological changes and reduced cell death (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7C</bold></xref>). To further elucidate the mode of <italic>Kpn</italic>-induced A549 cell death in the co-culture system, flow cytometry analysis was performed. The results indicated that <italic>Kpn</italic>-induced A549 cell death did not occur via apoptosis (<xref ref-type="fig" rid="f7"><bold>Figures&#xa0;7D, E</bold></xref>).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>6K2 inhibits cell death induced by <italic>Kpn</italic> infection. <bold>(A&#x2013;D)</bold><italic>Kpn</italic> and A549 cells were co-cultured under the same conditions in the presence or absence of 6K2 for 6 h, after which the following performants were conducted. <bold>(A)</bold> imaging was conducted to record the changes in the co-culture system. <bold>(B)</bold> the CFU of <italic>Kpn</italic> was analyzed. <bold>(C)</bold> morphological changes of A549 were conducted by microscopic examination. <bold>(D)</bold> A549 apoptosis were analyzed by flow cytometry. <bold>(E)</bold> Quantification of A549 apoptosis rates.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1749949-g007.tif">
<alt-text content-type="machine-generated">Panel A shows a colorimetric twelve-well plate with different conditions labeled mock, Ctrl, and 6K2. Panel B displays dot blot assays comparing two conditions across serial dilutions. Panel C presents three microscopy images of cells under mock, Ctrl, and 6K2 treatments. Panel D contains three flow cytometry dot plots of PI versus Annexin-FITC, each with quadrant percentages. Panel E features a bar graph of Annexin-FITC ratios in A549 cells comparing Ctrl, Kpn-12 hours, and Kpn-24 hours, annotated as non-significant.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_8">
<title>6K2 protects against lethal <italic>Kpn</italic> infection <italic>in vivo</italic></title>
<p>To determine whether 6K2 could protect against lethal <italic>Kpn</italic> infection <italic>in vivo</italic>, we first established a murine model of bloodstream infection using <italic>Kpn</italic>. Our results showed that mice administered <italic>Kpn</italic> at doses exceeding 1&#xd7;10<sup>8</sup> CFU exhibited 100% mortality within 24 hours, while a dose of 5&#xd7;10<sup>7</sup> CFU led to approximately 70% mortality within two days, accompanied by a transient decrease in body weight, followed by gradual recovery (<xref ref-type="fig" rid="f8"><bold>Figures&#xa0;8A, B</bold></xref>). Based on these findings, mice were infected with 1&#xd7;10<sup>8</sup> CFU of <italic>Kpn</italic> and treated with 6K2. During the mouse challenge and treatment experiment, the clinical symptoms of the mice were observed every 3h. The results demonstrated that all 6K2-treated mice survived, whereas all control mice died within 18h (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8C</bold></xref>). Blood samples collected at 1, 6, and 24h post 6K2 administration revealed that the bacterial load of <italic>Kpn</italic> in the blood&#xa0;of 6K2-treated mice fell below the detection limit as early as 6 hours after treatment (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8D</bold></xref>). Furthermore, quantification of 6K2 phage in the blood indicated high phage titers within 6&#xa0;hours&#xa0;of treatment, which subsequently decreased by 24 hours (<xref ref-type="fig" rid="f8"><bold>Figures&#xa0;8E, F</bold></xref>).</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Prompt phage treatment rescues mice with systemic <italic>Kpn</italic> infection. <bold>(A)</bold> Survival of mice after a single IP injection with the indicated inoculum (CFU) of <italic>Kpn</italic>. n = 10. <bold>(B)</bold> The weight of surviving mice was determined every day. <bold>(C)</bold> Survival of mice infected IP with <italic>Kpn</italic> (1&#xd7;10<sup>8</sup> CFU) followed by IP treatment with phage (MOI = 1, 10) 1h later. Equivalent volumes of PBS were injected in lieu of phage as control. For each group, For the <italic>Kpn</italic>-infected groups, n &#x2265; 5; for the groups injected with bacteriophages only, n = 3. <bold>(D)</bold> Blood was collected via the tail vein at 1, 6, and 24h post-phage treatment to determine the CFU of <italic>Kpn</italic> in the blood. <bold>(E, F)</bold> Blood samples were collected from the tail vein at 1, 6, and 24 h after phage administration to quantify phage 6K2 PFU in the bloodstream of phage-only control mice <bold>(E)</bold> and <italic>Kpn</italic>-infected mice <bold>(F)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1749949-g008.tif">
<alt-text content-type="machine-generated">Panel A shows a Kaplan-Meier survival curve with multiple treatment groups and PBS control, indicating varying survival rates over ten days. Panel B presents a line chart of body weight (grams) across treatment groups over ten days. Panel C displays another Kaplan-Meier survival curve with control and experimental groups over twenty-four hours. Panel D is a scatter plot with bacteria (log10 CFU per mL) on the y-axis for control, MOI 1, and MOI 10 groups at one, six, and twenty-four hours. Panel E is a scatter plot of phage levels (log10 PFU per mL) at one, six, and twenty-four hours for M1 and M10 groups. Panel F is a scatter plot showing phage levels in MOI 1 and MOI 10 groups over time.</alt-text>
</graphic></fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>A dearth of treatment options for infections caused by multidrug-resistant bacteria has led to renewed interest in the therapeutic potential of phage. Although numerous phage therapy cases have culminated in positive clinical outcomes. There are still some obstacles to be overcome. In addition to addressing issues such as the development of bacterial resistance to phages, it is of great significance for future clinical applications of phages to elucidate whether bacteria, phages, and bacterial lysates within the infectious microenvironment can trigger more intense immune responses and lead to the death of infected tissue cells. Recent years have witnessed a growing body of research highlighting the potential of bacteriophages in clearing bacterial infections and mitigating inflammatory responses, as demonstrated by <italic>in vitro</italic> and <italic>in vivo</italic> studies on the interactions among phages, bacteria, and host cells (<xref ref-type="bibr" rid="B31">Shi et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B10">Chen et&#xa0;al., 2025</xref>; <xref ref-type="bibr" rid="B41">Weissfuss et&#xa0;al., 2025</xref>). This research has moved beyond the binary interplay between phages and bacteria, increasingly reflecting the actual scenario of phage therapy during infection. Thus, further elucidation of the molecular mechanisms underlying the tripartite interaction among bacteriophages, bacteria, and host cells will provide critical insights to guide future clinical applications of phage-based therapies.</p>
<p>Bacteriophages are viruses capable of infecting and lysing bacteria. It is well known that animal viruses, such as SARS-CoV-2 and influenza viruses, trigger the host&#x2019;s antiviral innate immune response upon infecting host cells, primarily through viral nucleic acids such as DNA or RNA (<xref ref-type="bibr" rid="B18">Fu et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B42">Wu et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B6">Cao et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B48">Yang J. et&#xa0;al., 2024</xref>; <xref ref-type="bibr" rid="B50">Zhang et&#xa0;al., 2024</xref>). However, bacteriophages also contain nucleic acid components. While they are used to treat bacterial infections, it remains worth exploring whether they can trigger host antiviral innate immune responses. In our study, we found that bacteriophage treatment upregulates the expression of <italic>CXCL10</italic> in monocytes (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5D</bold></xref>). <italic>CXCL10</italic> is an interferon-induced cytokine (<xref ref-type="bibr" rid="B27">Mowat et&#xa0;al., 2021</xref>; <xref ref-type="bibr" rid="B20">Gervais et&#xa0;al., 2024</xref>), indicating that bacteriophages may activate the host antiviral innate immune response during application. Our further investigation revealed that both phages and bacterial lysates could activate the interferon signaling pathway and induce the expression of inflammatory cytokines and chemokines (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6</bold></xref>). Previous work has shown that two <italic>Kpn</italic> phages can suppress the inflammatory response induced by <italic>Kpn</italic> infection in bovine mammary epithelial cells (bMECs) <italic>in vitro</italic> (<xref ref-type="bibr" rid="B31">Shi et&#xa0;al., 2021</xref>). That study, however, did not explore whether phages themselves might act as inflammatory stimuli. This is an important consideration for the future use of bacteriophages in therapeutic contexts.</p>
<p>In our <italic>in vitro</italic> experiments, where phages and bacteria were co-cultured, the growth of phage-resistant mutant bacterial strains gradually outcompeted that of the wild-type strains as the bacteria mutated, leading to a loss of the phage&#x2019;s lytic activity. However, in our animal model, phage therapy demonstrated remarkably significant therapeutic efficacy (<xref ref-type="fig" rid="f8"><bold>Figures&#xa0;8C-F</bold></xref>), substantially inhibiting mortality in mice infected with <italic>Kpn</italic> and rapidly reducing the bacterial load in the blood within a short period. We did not observe the emergence of phage-resistant mutant bacterial strains <italic>in vivo</italic>. These phenomena differ from our <italic>in vitro</italic> findings, which may be attributed to the fact that, in the mouse infection model, in addition to the interaction between phages and bacteria, the mouse immune system-including immune cells (such as NK cells and macrophages) and antibodies-also contributes to the clearance of <italic>Kpn</italic>. When phage therapy is applied, the bacterial load of <italic>Kpn</italic> is rapidly reduced to a level that can be efficiently cleared by the host immune system. The remaining or mutant bacterial strains are subsequently eliminated through the synergistic action of the immune system, thereby achieving an optimal therapeutic outcome.</p>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Material</bold></xref>.</p></sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The animal study was approved by Jinan Microecological Biomedicine Shandong Laboratory Animal Ethics Committee/Jinan Microecological Biomedicine Shandong Laboratory. The study was conducted in accordance with the local legislation and institutional requirements.</p></sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>ZP: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing &#x2013; original draft. JF: Investigation, Writing &#x2013; original draft. XG: Investigation, Writing &#x2013; original draft. SZ: Investigation, Writing &#x2013; original draft. HZ: Investigation, Writing &#x2013; original draft. SL: Investigation, Writing &#x2013; original draft. LZ: Investigation, Writing &#x2013; original draft. GX: Investigation, Writing &#x2013; original draft. RL: Investigation, Writing &#x2013; original draft. TL: Investigation, Writing &#x2013; original draft. XL: Investigation, Writing &#x2013; original draft. YY: Investigation, Writing &#x2013; original draft. NWa: Formal analysis, Investigation, Methodology, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. CJ: Formal analysis, Methodology, Project administration, Writing &#x2013; review &amp; editing. NWu: Formal analysis, Funding acquisition, Project administration, Writing &#x2013; review &amp; editing.</p></sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s10" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If&#xa0;you identify any issues, please contact us.</p></sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcimb.2026.1749949/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcimb.2026.1749949/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
<supplementary-material xlink:href="Table2.xlsx" id="SM2" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"/></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Abdel-Razek</surname> <given-names>M. A.</given-names></name>
<name><surname>Nazeih</surname> <given-names>S. I.</given-names></name>
<name><surname>Yousef</surname> <given-names>N.</given-names></name>
<name><surname>Askoura</surname> <given-names>M.</given-names></name>
</person-group> (<year>2025</year>). 
<article-title>Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae</article-title>. <source>AMB Express</source> <volume>15</volume>, <fpage>37</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13568-025-01846-0</pub-id>, PMID: <pub-id pub-id-type="pmid">40044971</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Antimicrobial Resistance</surname> <given-names>C.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title>. <source>Lancet</source> <volume>399</volume>, <fpage>629</fpage>&#x2013;<lpage>655</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id>, PMID: <pub-id pub-id-type="pmid">35065702</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Berryhill</surname> <given-names>B.</given-names></name>
<name><surname>Gil-Gil</surname> <given-names>T.</given-names></name>
<name><surname>Smith</surname> <given-names>A. P.</given-names></name>
<name><surname>Levin</surname> <given-names>B. R.</given-names></name>
</person-group> (<year>2025</year>). 
<article-title>The future of phage therapy in the USA</article-title>. <source>Trends Mol. Med</source>. <fpage>982</fpage>&#x2013;<lpage>991</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molmed.2025.03.013</pub-id>, PMID: <pub-id pub-id-type="pmid">40268588</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Boeckman</surname> <given-names>J.</given-names></name>
<name><surname>Liu</surname> <given-names>M.</given-names></name>
<name><surname>Ramsey</surname> <given-names>J.</given-names></name>
<name><surname>Gill</surname> <given-names>J.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>Phage DNA extraction, genome assembly, and genome closure</article-title>. <source>Methods Mol. Biol.</source> <volume>2738</volume>, <fpage>125</fpage>&#x2013;<lpage>144</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-1-0716-3549-0_8</pub-id>, PMID: <pub-id pub-id-type="pmid">37966596</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Borish</surname> <given-names>L. C.</given-names></name>
<name><surname>Steinke</surname> <given-names>J. W.</given-names></name>
</person-group> (<year>2003</year>). 
<article-title>2. Cytokines and chemokines</article-title>. <source>J. Allergy Clin. Immunol.</source> <volume>111</volume>, <fpage>S460</fpage>&#x2013;<lpage>S475</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2005.07.001</pub-id>, PMID: <pub-id pub-id-type="pmid">16455343</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cao</surname> <given-names>D.</given-names></name>
<name><surname>Duan</surname> <given-names>L.</given-names></name>
<name><surname>Huang</surname> <given-names>B.</given-names></name>
<name><surname>Xiong</surname> <given-names>Y.</given-names></name>
<name><surname>Zhang</surname> <given-names>G.</given-names></name>
<name><surname>Huang</surname> <given-names>H.</given-names></name>
</person-group> (<year>2023</year>). 
<article-title>The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING</article-title>. <source>Sci. Signal</source> <volume>16</volume>, <elocation-id>eadd0082</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/scisignal.add0082</pub-id>, PMID: <pub-id pub-id-type="pmid">37130168</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chegini</surname> <given-names>Z.</given-names></name>
<name><surname>Khoshbayan</surname> <given-names>A.</given-names></name>
<name><surname>Vesal</surname> <given-names>S.</given-names></name>
<name><surname>Moradabadi</surname> <given-names>A.</given-names></name>
<name><surname>Hashemi</surname> <given-names>A.</given-names></name>
<name><surname>Shariati</surname> <given-names>A.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review</article-title>. <source>Ann. Clin. Microbiol. Antimicrob.</source> <volume>20</volume>, <fpage>30</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12941-021-00433-y</pub-id>, PMID: <pub-id pub-id-type="pmid">33902597</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>S.</given-names></name>
<name><surname>Zhou</surname> <given-names>Y.</given-names></name>
<name><surname>Chen</surname> <given-names>Y.</given-names></name>
<name><surname>Gu</surname> <given-names>J.</given-names></name>
</person-group> (<year>2018</year>). 
<article-title>fastp: an ultra-fast all-in-one FASTQ preprocessor</article-title>. <source>Bioinformatics</source> <volume>34</volume>, <fpage>i884</fpage>&#x2013;<lpage>i890</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/bioinformatics/bty560</pub-id>, PMID: <pub-id pub-id-type="pmid">30423086</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>H.</given-names></name>
<name><surname>Liu</surname> <given-names>H.</given-names></name>
<name><surname>Gong</surname> <given-names>Y.</given-names></name>
<name><surname>Dunstan</surname> <given-names>R. A.</given-names></name>
<name><surname>Ma</surname> <given-names>Z.</given-names></name>
<name><surname>Zhou</surname> <given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>A Klebsiella-phage cocktail to broaden the host range and delay bacteriophage resistance both <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>NPJ Biofilms Microbiomes</source> <volume>10</volume>, <fpage>127</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41522-024-00603-8</pub-id>, PMID: <pub-id pub-id-type="pmid">39543151</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>H.</given-names></name>
<name><surname>Sun</surname> <given-names>Y.</given-names></name>
<name><surname>Huang</surname> <given-names>Z.</given-names></name>
<name><surname>Zhao</surname> <given-names>D.</given-names></name>
<name><surname>Kong</surname> <given-names>J.</given-names></name>
<name><surname>Chen</surname> <given-names>H.</given-names></name>
<etal/>
</person-group>. (<year>2025</year>). 
<article-title>Evolving strategies of intracellular Hypervirulent Klebsiella pneumoniae during phage therapy: Reducing host autophagy and inflammation</article-title>. <source>Virulence</source> <volume>16</volume>, <fpage>2600148</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21505594.2025.2600148</pub-id>, PMID: <pub-id pub-id-type="pmid">41346207</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Crowley</surname> <given-names>L. C.</given-names></name>
<name><surname>Marfell</surname> <given-names>B. J.</given-names></name>
<name><surname>Scott</surname> <given-names>A. P.</given-names></name>
<name><surname>Waterhouse</surname> <given-names>N. J.</given-names></name>
</person-group> (<year>2016</year>). 
<article-title>Quantitation of apoptosis and necrosis by annexin V binding, propidium iodide uptake, and flow cytometry</article-title>. <source>Cold Spring Harb. Protoc.</source> <volume>2016</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/pdb.prot087288</pub-id>, PMID: <pub-id pub-id-type="pmid">27803250</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>David</surname> <given-names>S.</given-names></name>
<name><surname>Reuter</surname> <given-names>S.</given-names></name>
<name><surname>Harris</surname> <given-names>S. R.</given-names></name>
<name><surname>Glasner</surname> <given-names>C.</given-names></name>
<name><surname>Feltwell</surname> <given-names>T.</given-names></name>
<name><surname>Argimon</surname> <given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2019</year>). 
<article-title>Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial sp<italic>read</italic></article-title>. <source>Nat. Microbiol.</source> <volume>4</volume>, <fpage>1919</fpage>&#x2013;<lpage>1929</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41564-019-0492-8</pub-id>, PMID: <pub-id pub-id-type="pmid">31358985</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Duan</surname> <given-names>Y.</given-names></name>
<name><surname>Young</surname> <given-names>R.</given-names></name>
<name><surname>Schnabl</surname> <given-names>B.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Bacteriophages and their potential for treatment of gastrointestinal diseases</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source> <volume>19</volume>, <fpage>135</fpage>&#x2013;<lpage>144</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41575-021-00536-z</pub-id>, PMID: <pub-id pub-id-type="pmid">34782783</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fang</surname> <given-names>C.</given-names></name>
<name><surname>Dai</surname> <given-names>X.</given-names></name>
<name><surname>Xiang</surname> <given-names>L.</given-names></name>
<name><surname>Qiu</surname> <given-names>Y.</given-names></name>
<name><surname>Yin</surname> <given-names>M.</given-names></name>
<name><surname>Fu</surname> <given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2023</year>). 
<article-title>Isolation and characterization of three novel lytic phages against K54 serotype carbapenem-resistant hypervirulent Klebsiella pneumoniae</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>13</volume>, <elocation-id>1265011</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2023.1265011</pub-id>, PMID: <pub-id pub-id-type="pmid">38149011</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fang</surname> <given-names>Q.</given-names></name>
<name><surname>Yin</surname> <given-names>X.</given-names></name>
<name><surname>He</surname> <given-names>Y.</given-names></name>
<name><surname>Feng</surname> <given-names>Y.</given-names></name>
<name><surname>Zhang</surname> <given-names>L.</given-names></name>
<name><surname>Luo</surname> <given-names>H.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>Safety and efficacy of phage application in bacterial decolonisation: a systematic review</article-title>. <source>Lancet Microbe</source> <volume>5</volume>, <fpage>e489</fpage>&#x2013;<lpage>e499</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2666-5247(24)00002-8</pub-id>, PMID: <pub-id pub-id-type="pmid">38452780</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fang</surname> <given-names>Q.</given-names></name>
<name><surname>Zong</surname> <given-names>Z.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Lytic Phages against ST11 K47 Carbapenem-Resistant Klebsiella pneumoniae and the Corresponding Phage Resistance Mechanisms</article-title>. <source>mSphere</source> <volume>7</volume>, <elocation-id>e0008022</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/msphere.00080-22</pub-id>, PMID: <pub-id pub-id-type="pmid">35255715</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Federici</surname> <given-names>S.</given-names></name>
<name><surname>Kredo-Russo</surname> <given-names>S.</given-names></name>
<name><surname>Vald&#xe9;s-Mas</surname> <given-names>R.</given-names></name>
<name><surname>Kviatcovsky</surname> <given-names>D.</given-names></name>
<name><surname>Weinstock</surname> <given-names>E.</given-names></name>
<name><surname>Matiuhin</surname> <given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). 
<article-title>Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation</article-title>. <source>Cell</source> <volume>185</volume>, <fpage>2879</fpage>&#x2013;<lpage>2898 e24</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2022.07.003</pub-id>, PMID: <pub-id pub-id-type="pmid">35931020</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fu</surname> <given-names>Y. Z.</given-names></name>
<name><surname>Wang</surname> <given-names>S. Y.</given-names></name>
<name><surname>Zheng</surname> <given-names>Z. Q.</given-names></name>
<name><surname>Yi</surname> <given-names>H.</given-names></name>
<name><surname>Li</surname> <given-names>W. W.</given-names></name>
<name><surname>Xu</surname> <given-names>Z. S.</given-names></name>
<etal/>
</person-group>. (<year>2021</year>). 
<article-title>SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response</article-title>. <source>Cell Mol. Immunol.</source> <volume>18</volume>, <fpage>613</fpage>&#x2013;<lpage>620</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41423-020-00571-x</pub-id>, PMID: <pub-id pub-id-type="pmid">33110251</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Garc&#xed;a-Cruz</surname> <given-names>J. C.</given-names></name>
<name><surname>Rebollar-Juarez</surname> <given-names>X.</given-names></name>
<name><surname>Limones-Martinez</surname> <given-names>A.</given-names></name>
<name><surname>Santos-Lopez</surname> <given-names>C. S.</given-names></name>
<name><surname>Toya</surname> <given-names>S.</given-names></name>
<name><surname>Maeda</surname> <given-names>T.</given-names></name>
<etal/>
</person-group>. (<year>2023</year>). 
<article-title>Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in Pseudomonas aeruginosa</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>13</volume>, <elocation-id>1280265</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2023.1280265</pub-id>, PMID: <pub-id pub-id-type="pmid">38298921</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gervais</surname> <given-names>A.</given-names></name>
<name><surname>Le Floc'h</surname> <given-names>C.</given-names></name>
<name><surname>Le Voyer</surname> <given-names>T.</given-names></name>
<name><surname>Bizien</surname> <given-names>L.</given-names></name>
<name><surname>Bohlen</surname> <given-names>J.</given-names></name>
<name><surname>Celmeli</surname> <given-names>F.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>A sensitive assay for measuring whole-blood responses to type I IFNs</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>121</volume>, <elocation-id>e2402983121</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.2402983121</pub-id>, PMID: <pub-id pub-id-type="pmid">39312669</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hatfull</surname> <given-names>G. F.</given-names></name>
<name><surname>Dedrick</surname> <given-names>R. M.</given-names></name>
<name><surname>Schooley</surname> <given-names>R. T.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Phage therapy for antibiotic-resistant bacterial infections</article-title>. <source>Annu. Rev. Med.</source> <volume>73</volume>, <fpage>197</fpage>&#x2013;<lpage>211</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-med-080219-122208</pub-id>, PMID: <pub-id pub-id-type="pmid">34428079</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname> <given-names>Y.</given-names></name>
<name><surname>Huang</surname> <given-names>Y.</given-names></name>
<name><surname>Wu</surname> <given-names>Z.</given-names></name>
<name><surname>Fan</surname> <given-names>Z.</given-names></name>
<name><surname>Zheng</surname> <given-names>F.</given-names></name>
<name><surname>Liu</surname> <given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2025</year>). 
<article-title>Characterization and genomic insights into bacteriophages Kpph1 and Kpph9 against hypervirulent carbapenem-resistant Klebsiella pneumoniae</article-title>. <source>Virulence</source> <volume>16</volume>, <fpage>2450462</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21505594.2025.2450462</pub-id>, PMID: <pub-id pub-id-type="pmid">39803864</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jiang</surname> <given-names>W.</given-names></name>
<name><surname>Liu</surname> <given-names>J.</given-names></name>
<name><surname>Zhao</surname> <given-names>X.</given-names></name>
<name><surname>Yang</surname> <given-names>W.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Melatonin ameliorates lung cell inflammation and apoptosis caused by Klebsiella pneumoniae via AMP-activated protein kinase</article-title>. <source>Inflammopharmacology</source> <volume>30</volume>, <fpage>2345</fpage>&#x2013;<lpage>2357</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10787-022-01073-0</pub-id>, PMID: <pub-id pub-id-type="pmid">36131109</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>J.</given-names></name>
<name><surname>Yan</surname> <given-names>B.</given-names></name>
<name><surname>He</surname> <given-names>B.</given-names></name>
<name><surname>Li</surname> <given-names>L.</given-names></name>
<name><surname>Zhou</surname> <given-names>X.</given-names></name>
<name><surname>Wu</surname> <given-names>N.</given-names></name>
<etal/>
</person-group>. (<year>2023</year>). 
<article-title>Development of phage resistance in multidrug-resistant Klebsiella pneumoniae is associated with reduced virulence: a case report of a personalised phage therapy</article-title>. <source>Clin. Microbiol. Infect.</source> <volume>29</volume>, <fpage>1601 e1</fpage>&#x2013;<lpage>1601 e7</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmi.2023.08.022</pub-id>, PMID: <pub-id pub-id-type="pmid">37652124</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>L.</given-names></name>
<name><surname>Xu</surname> <given-names>X.</given-names></name>
<name><surname>Cheng</surname> <given-names>P.</given-names></name>
<name><surname>Yu</surname> <given-names>Z.</given-names></name>
<name><surname>Li</surname> <given-names>M.</given-names></name>
<name><surname>Yu</surname> <given-names>Z.</given-names></name>
<etal/>
</person-group>. (<year>2025</year>). 
<article-title>Klebsiella pneumoniae derived outer membrane vesicles mediated bacterial virulence, antibiotic resistance, host immune responses and clinical applications</article-title>. <source>Virulence</source> <volume>16</volume>, <fpage>2449722</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21505594.2025.2449722</pub-id>, PMID: <pub-id pub-id-type="pmid">39792030</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mirza</surname> <given-names>K. A.</given-names></name>
<name><surname>Tchatchiashvili</surname> <given-names>T.</given-names></name>
<name><surname>Marquet</surname> <given-names>M.</given-names></name>
<name><surname>Nietzsche</surname> <given-names>S.</given-names></name>
<name><surname>Pletz</surname> <given-names>M. W.</given-names></name>
<name><surname>Makarewicz</surname> <given-names>O.</given-names></name>
</person-group> (<year>2025</year>). 
<article-title>Characterization and genome analysis of novel Klebsiella pneumoniae phage vbKpUKJ_2 isolated from hospital sewage water</article-title>. <source>BMC Microbiol.</source> <volume>25</volume>, <fpage>96</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12866-025-03813-y</pub-id>, PMID: <pub-id pub-id-type="pmid">40011819</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mowat</surname> <given-names>C.</given-names></name>
<name><surname>Mosley</surname> <given-names>S. R.</given-names></name>
<name><surname>Namdar</surname> <given-names>A.</given-names></name>
<name><surname>Schiller</surname> <given-names>D.</given-names></name>
<name><surname>Baker</surname> <given-names>K.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10</article-title>. <source>J. Exp. Med.</source> <volume>218</volume>, <fpage>e20210108</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20210108</pub-id>, PMID: <pub-id pub-id-type="pmid">34297038</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nurk</surname> <given-names>S.</given-names></name>
<name><surname>Meleshko</surname> <given-names>D.</given-names></name>
<name><surname>Korobeynikov</surname> <given-names>A.</given-names></name>
<name><surname>Pevzner</surname> <given-names>P. A.</given-names></name>
</person-group> (<year>2017</year>). 
<article-title>metaSPAdes: a new versatile metagenomic assembler</article-title>. <source>Genome Res.</source> <volume>27</volume>, <fpage>824</fpage>&#x2013;<lpage>834</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/gr.213959.116</pub-id>, PMID: <pub-id pub-id-type="pmid">28298430</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rio</surname> <given-names>D. C.</given-names></name>
<name><surname>Ares</surname> <given-names>M. Jr.</given-names></name>
<name><surname>Hannon</surname> <given-names>G. J.</given-names></name>
<name><surname>Nilsen</surname> <given-names>T. W.</given-names></name>
</person-group> (<year>2010</year>). 
<article-title>Purification of RNA using TRIzol (TRI reagent)</article-title>. <source>Cold Spring Harb. Protoc.</source> <volume>2010</volume>, <fpage>pdb prot5439</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/pdb.prot5439</pub-id>, PMID: <pub-id pub-id-type="pmid">20516177</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ryu</surname> <given-names>J. K.</given-names></name>
<name><surname>Kim</surname> <given-names>S. J.</given-names></name>
<name><surname>Rah</surname> <given-names>S. H.</given-names></name>
<name><surname>Kang</surname> <given-names>J. I.</given-names></name>
<name><surname>Jung</surname> <given-names>H. E.</given-names></name>
<name><surname>Lee</surname> <given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2017</year>). 
<article-title>Reconstruction of LPS transfer cascade reveals structural determinants within LBP, CD14, and TLR4-MD2 for efficient LPS recognition and transfer</article-title>. <source>Immunity</source> <volume>46</volume>, <fpage>38</fpage>&#x2013;<lpage>50</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2016.11.007</pub-id>, PMID: <pub-id pub-id-type="pmid">27986454</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shi</surname> <given-names>Y.</given-names></name>
<name><surname>Zhao</surname> <given-names>W.</given-names></name>
<name><surname>Liu</surname> <given-names>G.</given-names></name>
<name><surname>Ali</surname> <given-names>T.</given-names></name>
<name><surname>Chen</surname> <given-names>P.</given-names></name>
<name><surname>Liu</surname> <given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2021</year>). 
<article-title>Bacteriophages isolated from dairy farm mitigated Klebsiella pneumoniae-induced inflammation in bovine mammary epithelial cells cultured <italic>in vitro</italic></article-title>. <source>BMC Vet. Res.</source> <volume>17</volume>, <fpage>37</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12917-020-02738-0</pub-id>, PMID: <pub-id pub-id-type="pmid">33468111</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Strathdee</surname> <given-names>S. A.</given-names></name>
<name><surname>Hatfull</surname> <given-names>G. F.</given-names></name>
<name><surname>Mutalik</surname> <given-names>V. K.</given-names></name>
<name><surname>Schooley</surname> <given-names>R. T.</given-names></name>
</person-group> (<year>2023</year>). 
<article-title>Phage therapy: From biological mechanisms to future directions</article-title>. <source>Cell</source> <volume>186</volume>, <fpage>17</fpage>&#x2013;<lpage>31</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2022.11.017</pub-id>, PMID: <pub-id pub-id-type="pmid">36608652</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tang</surname> <given-names>Y.</given-names></name>
<name><surname>Chen</surname> <given-names>L.</given-names></name>
<name><surname>Yang</surname> <given-names>J.</given-names></name>
<name><surname>Zhang</surname> <given-names>S.</given-names></name>
<name><surname>Jin</surname> <given-names>J.</given-names></name>
<name><surname>Wei</surname> <given-names>Y.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>Gut microbes improve prognosis of Klebsiella pneumoniae pulmonary infection through the lung-gut axis</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>14</volume>, <elocation-id>1392376</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2024.1392376</pub-id>, PMID: <pub-id pub-id-type="pmid">38903943</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Torres-Barcelo</surname> <given-names>C.</given-names></name>
<name><surname>Hochberg</surname> <given-names>M. E.</given-names></name>
</person-group> (<year>2016</year>). 
<article-title>Evolutionary rationale for phages as complements of antibiotics</article-title>. <source>Trends Microbiol.</source> <volume>24</volume>, <fpage>249</fpage>&#x2013;<lpage>256</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tim.2015.12.011</pub-id>, PMID: <pub-id pub-id-type="pmid">26786863</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Uyttebroek</surname> <given-names>S.</given-names></name>
<name><surname>Chen</surname> <given-names>B.</given-names></name>
<name><surname>Onsea</surname> <given-names>J.</given-names></name>
<name><surname>Ruythooren</surname> <given-names>F.</given-names></name>
<name><surname>Debaveye</surname> <given-names>Y.</given-names></name>
<name><surname>Devolder</surname> <given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). 
<article-title>Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review</article-title>. <source>Lancet Infect. Dis.</source> <volume>22</volume>, <fpage>e208</fpage>&#x2013;<lpage>e220</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00612-5</pub-id>, PMID: <pub-id pub-id-type="pmid">35248167</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>van der Vorst</surname> <given-names>E. P.</given-names></name>
<name><surname>Doring</surname> <given-names>Y.</given-names></name>
<name><surname>Weber</surname> <given-names>C.</given-names></name>
</person-group> (<year>2015</year>). 
<article-title>Chemokines</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source> <volume>35</volume>, <fpage>e52</fpage>&#x2013;<lpage>e56</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/ATVBAHA.115.306359</pub-id>, PMID: <pub-id pub-id-type="pmid">26490276</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>Z.</given-names></name>
<name><surname>Ren</surname> <given-names>J.</given-names></name>
<name><surname>Liu</surname> <given-names>Q.</given-names></name>
<name><surname>Li</surname> <given-names>J.</given-names></name>
<name><surname>Wu</surname> <given-names>X.</given-names></name>
<name><surname>Wang</surname> <given-names>W.</given-names></name>
<etal/>
</person-group>. (<year>2018</year>). 
<article-title>Hypermucoviscous Klebsiella pneumoniae infections induce platelet aggregation and apoptosis and inhibit maturation of megakaryocytes</article-title>. <source>Thromb. Res.</source> <volume>171</volume>, <fpage>45</fpage>&#x2013;<lpage>54</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.thromres.2018.09.053</pub-id>, PMID: <pub-id pub-id-type="pmid">30248660</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>X.</given-names></name>
<name><surname>Bi</surname> <given-names>C.</given-names></name>
<name><surname>Xin</surname> <given-names>X.</given-names></name>
<name><surname>Zhang</surname> <given-names>M.</given-names></name>
<name><surname>Fu</surname> <given-names>H.</given-names></name>
<name><surname>Lan</surname> <given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2023</year>). 
<article-title>Pyroptosis, apoptosis, and autophagy are involved in infection induced by two clinical Klebsiella pneumoniae isolates with different virulence</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>13</volume>, <elocation-id>1165609</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2023.1165609</pub-id>, PMID: <pub-id pub-id-type="pmid">37223846</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname> <given-names>S.</given-names></name>
<name><surname>Xu</surname> <given-names>T.</given-names></name>
<name><surname>Chen</surname> <given-names>Y.</given-names></name>
<name><surname>Zhou</surname> <given-names>K.</given-names></name>
</person-group> (<year>2023</year>). 
<article-title>Autophagy, cell death, and cytokines in K. pneumoniae infection: therapeutic perspectives</article-title>. <source>Emerg. Microbes Infect.</source> <volume>12</volume>, <fpage>2140607</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/22221751.2022.2140607</pub-id>, PMID: <pub-id pub-id-type="pmid">36287114</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname> <given-names>R.</given-names></name>
<name><surname>Zeng</surname> <given-names>Z.</given-names></name>
<name><surname>Chen</surname> <given-names>S.</given-names></name>
<name><surname>Shi</surname> <given-names>Y.</given-names></name>
<name><surname>Ding</surname> <given-names>Q.</given-names></name>
</person-group> (<year>2025</year>). 
<article-title>Qingfei Litan decoction alleviated Klebsiella pneumoniae-induced pneumonia by targeting the TLR4/MyD88/NF-kappaB axis via miR-146a-5p</article-title>. <source>J. Ethnopharmacol.</source> <volume>349</volume>, <fpage>119947</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jep.2025.119947</pub-id>, PMID: <pub-id pub-id-type="pmid">40378935</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Weissfuss</surname> <given-names>C.</given-names></name>
<name><surname>Hoffmann</surname> <given-names>K.</given-names></name>
<name><surname>Behrendt</surname> <given-names>U.</given-names></name>
<name><surname>B&#xfc;rkle</surname> <given-names>M.</given-names></name>
<name><surname>Twamley</surname> <given-names>S. G.</given-names></name>
<name><surname>Korf</surname> <given-names>I. H. E.</given-names></name>
<etal/>
</person-group>. (<year>2025</year>). 
<article-title>Neutrophils, not macrophages, aid phage-mediated control of pulmonary Pseudomonas aeruginosa infection</article-title>. <source>Front. Immunol.</source> <volume>16</volume>, <elocation-id>1681461</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2025.1681461</pub-id>, PMID: <pub-id pub-id-type="pmid">41346627</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname> <given-names>J.</given-names></name>
<name><surname>Shi</surname> <given-names>Y.</given-names></name>
<name><surname>Pan</surname> <given-names>X.</given-names></name>
<name><surname>Wu</surname> <given-names>S.</given-names></name>
<name><surname>Hou</surname> <given-names>R.</given-names></name>
<name><surname>Zhang</surname> <given-names>Y.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO</article-title>. <source>Cell Rep.</source> <volume>34</volume>, <fpage>108761</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2021.108761</pub-id>, PMID: <pub-id pub-id-type="pmid">33567255</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wyres</surname> <given-names>K. L.</given-names></name>
<name><surname>Lam</surname> <given-names>M. M. C.</given-names></name>
<name><surname>Holt</surname> <given-names>K. E.</given-names></name>
</person-group> (<year>2020</year>). 
<article-title>Population genomics of Klebsiella pneumoniae</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>18</volume>, <fpage>344</fpage>&#x2013;<lpage>359</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41579-019-0315-1</pub-id>, PMID: <pub-id pub-id-type="pmid">32055025</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname> <given-names>L.</given-names></name>
<name><surname>Li</surname> <given-names>J.</given-names></name>
<name><surname>Wu</surname> <given-names>W.</given-names></name>
<name><surname>Wu</surname> <given-names>X.</given-names></name>
<name><surname>Ren</surname> <given-names>J.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>Klebsiella pneumoniae capsular polysaccharide: Mechanism in regulation of synthesis, virulence, and pathogenicity</article-title>. <source>Virulence</source> <volume>15</volume>, <fpage>2439509</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21505594.2024.2439509</pub-id>, PMID: <pub-id pub-id-type="pmid">39668724</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname> <given-names>X.</given-names></name>
<name><surname>Dong</surname> <given-names>N.</given-names></name>
<name><surname>Chan</surname> <given-names>E. W.</given-names></name>
<name><surname>Zhang</surname> <given-names>R.</given-names></name>
<name><surname>Chen</surname> <given-names>S.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Carbapenem resistance-encoding and virulence-encoding conjugative plasmids in klebsiella pneumoniae</article-title>. <source>Trends Microbiol.</source> <volume>29</volume>, <fpage>65</fpage>&#x2013;<lpage>83</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tim.2020.04.012</pub-id>, PMID: <pub-id pub-id-type="pmid">32448764</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname> <given-names>Y.</given-names></name>
<name><surname>Yang</surname> <given-names>Y.</given-names></name>
<name><surname>Chen</surname> <given-names>G.</given-names></name>
<name><surname>Lin</surname> <given-names>M.</given-names></name>
<name><surname>Chen</surname> <given-names>Y.</given-names></name>
<name><surname>He</surname> <given-names>R.</given-names></name>
<etal/>
</person-group>. (<year>2021</year>). 
<article-title>Molecular characterization of carbapenem-resistant and virulent plasmids in Klebsiella pneumoniae from patients with bloodstream infections in China</article-title>. <source>Emerg. Microbes Infect.</source> <volume>10</volume>, <fpage>700</fpage>&#x2013;<lpage>709</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/22221751.2021.1906163</pub-id>, PMID: <pub-id pub-id-type="pmid">33739229</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname> <given-names>Y. Y.</given-names></name>
<name><surname>Tsai</surname> <given-names>I. T.</given-names></name>
<name><surname>Lai</surname> <given-names>C. H.</given-names></name>
<name><surname>Chen</surname> <given-names>C. P.</given-names></name>
<name><surname>Chen</surname> <given-names>C. C.</given-names></name>
<name><surname>Hsu</surname> <given-names>Y. C.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>Time to positivity of Klebsiella pneumoniae in blood cultures as prognostic marker in patients with intra-abdominal infection: A retrospective study</article-title>. <source>Virulence</source> <volume>15</volume>, <fpage>2329397</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21505594.2024.2329397</pub-id>, PMID: <pub-id pub-id-type="pmid">38548677</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname> <given-names>J.</given-names></name>
<name><surname>Li</surname> <given-names>W.</given-names></name>
<name><surname>Zhang</surname> <given-names>Z.</given-names></name>
<name><surname>Gong</surname> <given-names>X.</given-names></name>
<name><surname>Chen</surname> <given-names>Y.</given-names></name>
<name><surname>Peng</surname> <given-names>X.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>Targeting PRMT7-mediated monomethylation of MAVS enhances antiviral innate immune responses and inhibits RNA virus replication</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>121</volume>, <elocation-id>e2408117121</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.2408117121</pub-id>, PMID: <pub-id pub-id-type="pmid">39546576</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>F.</given-names></name>
<name><surname>Zhong</surname> <given-names>J.</given-names></name>
<name><surname>Ding</surname> <given-names>H.</given-names></name>
<name><surname>Liao</surname> <given-names>G.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant klebsiella pneumoniae infection after kidney transplantation</article-title>. <source>Infect. Drug Resist.</source> <volume>14</volume>, <fpage>5165</fpage>&#x2013;<lpage>5174</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/IDR.S343505</pub-id>, PMID: <pub-id pub-id-type="pmid">34908850</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>X.</given-names></name>
<name><surname>Zhang</surname> <given-names>Y.</given-names></name>
<name><surname>Wei</surname> <given-names>F.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>Research progress on the nonstructural protein 1 (NS1) of influenza a virus</article-title>. <source>Virulence</source> <volume>15</volume>, <fpage>2359470</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21505594.2024.2359470</pub-id>, PMID: <pub-id pub-id-type="pmid">38918890</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>R.</given-names></name>
<name><surname>Jiang</surname> <given-names>S.</given-names></name>
<name><surname>Ren</surname> <given-names>S.</given-names></name>
<name><surname>Yang</surname> <given-names>L.</given-names></name>
<name><surname>Han</surname> <given-names>W.</given-names></name>
<name><surname>Guo</surname> <given-names>Z.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>A novel phage putative depolymerase, Depo16, has specific activity against K1 capsular-type Klebsiella pneumoniae</article-title>. <source>Appl. Environ. Microbiol.</source> <volume>90</volume>, <fpage>e0119723</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/aem.01197-23</pub-id>, PMID: <pub-id pub-id-type="pmid">38551353</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>M.</given-names></name>
<name><surname>Li</surname> <given-names>H.</given-names></name>
<name><surname>Gan</surname> <given-names>D.</given-names></name>
<name><surname>Wang</surname> <given-names>M.</given-names></name>
<name><surname>Deng</surname> <given-names>H.</given-names></name>
<name><surname>Yang</surname> <given-names>Q. E.</given-names></name>
</person-group> (<year>2024</year>). 
<article-title>Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic Klebsiella pneumoniae</article-title>. <source>mSystems</source> <volume>9</volume>, <elocation-id>e0060724</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/msystems.00607-24</pub-id>, PMID: <pub-id pub-id-type="pmid">39166877</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zheng</surname> <given-names>M. M.</given-names></name>
<name><surname>Guo</surname> <given-names>M. X.</given-names></name>
<name><surname>Shang</surname> <given-names>L. M.</given-names></name>
<name><surname>Zhang</surname> <given-names>J.</given-names></name>
<name><surname>Lin</surname> <given-names>J.</given-names></name>
<name><surname>Tian</surname> <given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). 
<article-title>Effect of carbapenem-resistant klebsiella pneumoniae infection on the clinical outcomes of kidney transplant recipients</article-title>. <source>Infect. Drug Resist.</source> <volume>15</volume>, <fpage>6471</fpage>&#x2013;<lpage>6483</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/IDR.S381265</pub-id>, PMID: <pub-id pub-id-type="pmid">36353378</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname> <given-names>W.</given-names></name>
<name><surname>Feng</surname> <given-names>Y.</given-names></name>
<name><surname>Zong</surname> <given-names>Z.</given-names></name>
</person-group> (<year>2018</year>). 
<article-title>Two new lytic bacteriophages of the myoviridae family against carbapenem-resistant acinetobacter baumannii</article-title>. <source>Front. Microbiol.</source> <volume>9</volume>, <elocation-id>850</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2018.00850</pub-id>, PMID: <pub-id pub-id-type="pmid">29760690</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/48691">Gill Diamond</ext-link>, University of Louisville, United States</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/647085">Iqbal Ahmad Alvi</ext-link>, Hazara University, Pakistan</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3026660">Kokkarambath Vannadil Suchithra</ext-link>, K. S. Hegde Medical Academy, India</p></fn>
</fn-group>
</back>
</article>